Table 1.
Baseline characteristics
| Total cohort (N = 928) | ICM (N = 438) | NIDCM (N = 490) | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Men, % (n) | 647 (70) | 362 (83) | 285 (58) | <0.001 |
| Age, years | 66 ± 11 | 69 ± 7 | 63 ± 11 | <0.001 |
| BMI, kg/m2 | 26.7 ± 4.6 | 26.8 ± 4.2 | 26.7 ± 5.0 | 0.79 |
| Weight, kg | 81 ± 16 | 82 ± 14 | 80 ± 18 | 0.19 |
| Height, cm | 174 ± 9 | 175 ± 8 | 173 ± 10 | 0.01 |
| Medical history | ||||
| Hypertension, % (n) | 397 (43) | 193 (44) | 204 (42) | 0.51 |
| Diabetes mellitus, % (n) | 207 (22) | 120 (27) | 84 (18) | 0.001 |
| (History of) AF, % (n) | 130 (14) | 60 (14) | 70 (14) | 0.85 |
| Clinical profile | ||||
| NYHA class, % (n) | 0.19 | |||
| I | 19 (2) | 4 (1) | 15 (3) | |
| II | 345 (37) | 165 (37) | 180 (37) | |
| III | 515 (55) | 246 (56) | 265 (54) | |
| IV | 39 (4) | 20 (5) | 19 (4) | |
| Missing | 14 (2) | 3 (1) | 11 (2) | |
| ECG | ||||
| Heart rate, bpm | 73 ± 15 | 71 ± 15 | 74 ± 16 | 0.02 |
| PQ duration, ms | 189 ± 38 | 195 ± 38 | 184 ± 38 | <0.001 |
| QRS duration, ms | 161 ± 20 | 160 ± 19 | 162 ± 21 | 0.11 |
| QT duration, ms | 485 ± 41 | 481 ± 41 | 489 ± 40 | 0.002 |
| LBBB, % (n) | 746 (80) | 327 (75) | 419 (86) | <0.001 |
| Echocardiography | ||||
| LVEF, % | 24 ± 9 | 24 ± 8 | 25 ± 9 | 0.02 |
| LVEDV, mL | 220 ± 89 | 231 ± 83 | 211 ± 93 | 0.001 |
| LVESV, mL | 169 ± 78 | 178 ± 74 | 161 ± 80 | 0.001 |
| Mitral regurgitation, % (n) | 0.03 | |||
| Mild | 271 (33) | 118 (41) | 153 (31) | |
| Mild‐moderate | 174 (21) | 98 (22) | 76 (16) | |
| Moderate‐severe/severe | 130 (16) | 66 (15) | 64 (13) | |
| Implantation | ||||
| Device type | 0.11 | |||
| CRT‐P, % (n) | 60 (7) | 22 (5) | 38 (8) | |
| CRT‐D, % (n) | 868 (93) | 416 (95) | 452 (92) | |
| Lead position | 0.96 | |||
| Anterior | 7 (1) | 4 (1) | 3 (1) | |
| Anterolateral | 94 (10) | 46 (11) | 48 (10) | |
| Lateral | 320 (34) | 146 (33) | 174 (35) | |
| Posterolateral | 405 (44) | 188 (43) | 217 (44) | |
| Posterior | 76 (8) | 36 (8) | 40 (8) | |
| Missing | 26 (3) | 18 (4) | 8 (2) | |
| Medication use | ||||
| β‐blocker, % (n) | 794 (86) | 377 (86) | 417 (85) | 0.71 |
| ACEi or ARB, % (n) | 850 (92) | 396 (90) | 454 (93) | 0.24 |
| MRA, % (n) | 254 (27) | 107 (24) | 147 (30) | 0.80 |
| Diuretics, % (n) | 741 (80) | 358 (82) | 383 (78) | 0.19 |
| Statin, % (n) | 531 (57) | 353 (81) | 178 (36) | <0.001 |
| Digoxin, % (n) | 134 (14) | 57 (13) | 77 (16) | 0.26 |
| Antiarrhythmic drugs, % (n) | 93 (10) | 49 (11) | 44 (9) | 0.28 |
| Laboratory values | ||||
| NT‐proBNP (pg/mL) | 1301 [541–2856] | 1490 [750–3034] | 1107 [394–2770] | 0.002 |
| Hb (mmol/L) | 8.5 [7.7–9.1] | 8.5 [7.7–9.1] | 8.5 [7.8–9.0] | 0.99 |
| Creatinine (umol/L) | 102 [83–129] | 111[91–137] | 92 [79–119] | <0.001 |
| eGFR (mL/min/1.73m2) | 65 [48–90] | 60 [44–79] | 71 [51–96] | <0.001 |
ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CRT‐P, cardiac resynchronization therapy pacemaker; CRT‐D, cardiac resynchronization therapy defibrillator; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; MRA, mineralocorticoid receptor antagonist; NIDCM, non‐ischaemic dilated cardiomyopathy; NT‐proBNP, N terminal brain natriuretic peptide; NYHA, New York Heart Association.